A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 5, 2011

Boosting Agent Cobicistat Comparable to Norvir in Phase III Study

Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and no more likely to discontinue therapy due to side effects, according to preliminary results from a Phase III study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine). The study’s findings, highlighted in a December 5 statement from cobicistat’s developer Gilead Sciences, will be presented in full at a scientific conference sometime in 2012, with an approval application likely to be submitted to the FDA sometime this spring.

Cobicistat, formerly known as GS-9350, is an experimental pharmacokinetic enhancer—a drug used to boost other medications in the blood to make them more effective. It is being developed as an alternative to Norvir, a protease inhibitor (PI) once used to treat HIV but now prescribed at low doses to boost the blood levels of other PIs, notably Reyataz, Lexiva (fosamprenavir), Prezista (darunavir), Aptivus (tipranavir) and Kaletra (lopinavir plus ritonavir).

Cobicistat’s potential as a Norvir alternative is important. For starters, while it has a pronounced effect on the enzyme system (CYP3A) responsible for breaking down several HIV drugs, it doesn’t affect other enzyme systems used by many other medications—a common problem with Norvir that contributes to numerous potentially harmful drug interactions. The drug also doesn’t impair fat cell functions like Norvir does, at least not in test tube studies, meaning that cobicistat may be less likely to count fat accumulation and insulin sensitivity problems as side effects.

Gilead has been committed to testing cobicistat as a stand-alone drug in combination with other companies’ drugs that generally require boosting. Gilead is also exploring cobicistat in combination with its experimental integrase inhibitor elvitegravir and Truvada as a once-daily fixed-dose combination tablet.   

Study 114, a Phase III clinical trial, was conducted by Gilead to explore the effectiveness and safety of cobicistat-boosted Reyataz versus Norvir-boosted Reyataz over a 96-week period at more than 200 study sites internationally. The researchers allotted nearly 700 HIV-positive individuals starting antiretroviral therapy for the first time to receive 150 milligrams (mg) cobicistat of 100 mg Norvir, both in combination with Reyataz and Truvada (tenofovir plus emtricitabine). 

Similar rates of virologic suppression—defined as a viral load below 50 copies—were maintained through the follow-up period. After 48 weeks of treatment, 85 percent in the cobicistat group and 87 percent in the Norvir group had viral loads below 50 copies/mL. Given the similar response rates in the two groups, cobicistat was considered to be “non-inferior” to Norvir.

As for adverse health outcomes, the Gilead statement notes similar side effect-related discontinuation rates in both groups. Approximately 7.3 percent of those receiving cobicistat-boosted Reyataz plus Truvada discontinued therapy because of adverse events, compared with 7.2 percent of patients receiving Norvir-boosted Reyataz plus Truvada.

One particular adverse event was noted in the press release. Small increases in serum creatinine—a lab test used to measure kidney function—with resulting decreases in estimated creatine clearance were observed in the study. After 48 weeks of treatment, the average increase in serum creatinine was 0.14 milligrams per deciliter (mg/dL) among those receiving cobicistat, compared with a 0.09 mg/dL serum creatinine increase among those in the Norvir group.

“The increase in serum creatinine with cobicistat occurs with days of drug initiation and is reversible with values returning to [pre-treatment levels] with days after [discontinuing] cobicistat,” Gilead clarifies, adding that cobicistat didn’t have an effect on other measures of renal function,  including actual glomerular filtrates rates (GFR).

“These results demonstrate that cobicistat may provide patients taking protease-based regimens with a much-needed alternative boosting agent,” Norbert Bischofberger, PhD, Gilead’s chief scientific officer, is quoted as saying in the statement. “We are now working toward a second quarter 2012 U.S. regulatory filing for cobicistat.”

Search: cobicistat, ritonavir, Norvir, Gilead, quad, non-inferior, comparable


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chrisf
    san jose
    California


    Reginaldb06
    Dallas
    Texas


    TaintedloveDC
    Washington
    DC


    robert12
    Queens
    New York
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.